A 503A pharmacy is a traditional compounding pharmacy: it prepares a drug for one identified patient against a valid prescription and is overseen mainly by its state board of pharmacy. A 503B outsourcing facility is a sterile-compounding operation that registers with FDA, can make batches, must follow current good manufacturing practice (CGMP) and is inspected by FDA on a risk-based schedule. Neither one turns a compounded peptide into an FDA-approved drug, and neither can lawfully compound a substance the law doesn't let it start from.
Why this matters right now
Peptide interest jumped after the July 2026 meeting of FDA's Pharmacy Compounding Advisory Committee (PCAC), and so did the number of clinics promising "pharmacy-made" peptides. Most of the confusion comes from treating three separate events as one: an advisory vote, a decision by FDA, and formal placement on a list that allows compounding. We cover those steps in detail in the 503A bulks list explainer. This post is about the pharmacies at the end of that chain, and what the 503A or 503B label tells you about the vial you'd receive.
503A in plain terms
Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding: a licensed pharmacist or physician preparing a customized medication for an identified individual patient based on a prescription. Think one patient, one order. These pharmacies are licensed and inspected mainly by state boards of pharmacy, and they generally follow the United States Pharmacopeia's compounding standards as adopted by their state.
The key constraint is what a 503A pharmacy may start from. Bulk drug substances have to meet one of three conditions:
- be a component of an FDA-approved drug,
- be the subject of a USP or NF monograph, or
- appear on FDA's 503A bulks list.
That third door is what the PCAC process feeds. A favorable committee vote is a non-binding recommendation. Placement on the list comes later, through FDA rulemaking. Until that happens, a 503A pharmacy can't treat a peptide like BPC-157 as eligible just because the committee liked it. Our BPC-157 PCAC breakdown explains what the vote did and didn't change.
503B in plain terms
Section 503B was created by the Drug Quality and Security Act of 2013. According to FDA, an outsourcing facility is a facility at one location that compounds sterile drugs, has elected to register as an outsourcing facility, and complies with section 503B. The trade-offs look like this:
- Batch production is allowed. An outsourcing facility can compound with or without patient-specific prescriptions, which is how hospitals and clinics stock office-use products.
- CGMP applies. FDA says outsourcing facilities' products can be exempt from FDA approval and from some labeling rules, but not from CGMP requirements.
- FDA inspects. FDA inspects outsourcing facilities on a risk-based schedule.
- Reporting is mandatory. Facilities must report adverse events and submit a list of what they compounded over the previous six months, at registration and every June and December.
FDA keeps a public list of registered outsourcing facilities, so you can check a name a clinic gives you.
Side-by-side comparison
| Feature | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Who it serves | An identified patient with a prescription | Patients and providers; may produce batches without patient-specific prescriptions |
| Main regulator | State board of pharmacy | FDA (plus state licensure) |
| Manufacturing standard | USP compounding standards as adopted by the state | Federal CGMP |
| FDA inspection | Not routine | Risk-based schedule |
| Product reporting to FDA | No routine product lists | Product lists every June and December; adverse event reports |
| Starting ingredients | Approved-drug component, USP/NF monograph, or 503A bulks list | Its own bulks framework, centered on clinical need, or drugs on FDA's shortage list |
| FDA-approved product? | No | No |
The limits that apply to both
Biologics are off the table
On March 23, 2020, a group of protein products approved as drugs were transitioned to biologics. FDA's notice to compounders says these transitioning products "will not be eligible for the exemptions for compounded drugs," and that biological products licensed under the Public Health Service Act aren't eligible either. FDA's transition list includes chorionic gonadotropin (Novarel and Pregnyl) and tesamorelin (Egrifta and Egrifta SV). Practically, a clinic offering "compounded hCG" or "compounded tesamorelin" is offering something FDA's own documents say falls outside the compounding exemptions.
"Essentially a copy" of an approved drug
Compounders aren't supposed to make what amounts to a copy of a commercially available approved drug. That rule is why the GLP-1 market changed so sharply after the semaglutide and tirzepatide shortages ended. FDA's current GLP-1 consumer page says compounded drugs should be used only when an FDA-approved drug can't meet a patient's medical needs. It also says salt forms such as semaglutide sodium and semaglutide acetate have no known lawful basis for compounding, and that retatrutide and cagrilintide can't be used in compounding under federal law.
Not approved means not reviewed
Whether 503A or 503B, a compounded drug hasn't been through FDA's premarket review for safety, effectiveness or quality. For peptides with little human data, that review gap is on top of an evidence gap.
What it means for your prescription
For an individual man getting a compounded peptide through telehealth, the most common setup is a 503A pharmacy filling a patient-specific prescription. That isn't a problem by itself. Many 503A pharmacies run tight operations. It just means that quality depends heavily on that pharmacy's own practices and its state's oversight, so the questions you ask matter more.
A 503B source brings CGMP and FDA inspection, which are meaningful protections. But it doesn't make an ineligible substance eligible, and a 503B label doesn't tell you anything about whether the peptide works.
Potency and sterility testing on the batch or preparation, a beyond-use date, a named pharmacist you can contact, and a pharmacy license that covers your state. If you're used to research-vendor paperwork, the logic carries over: read the documents, don't trust the label. Our COA guide covers how to read test reports.
Questions to ask the clinic or pharmacy
- Which pharmacy will fill this, and is it a 503A pharmacy or a registered 503B outsourcing facility?
- Is the pharmacy licensed in my state?
- What is the legal basis for compounding this specific ingredient: an approved-drug component, a USP monograph, or a bulks list?
- Is this a biologic, or a salt form FDA has flagged?
- What testing does the pharmacy do for potency and sterility, and can I see results?
- Who do I call at the pharmacy with a question about the product?
For the clinic side of the same vetting job, use our 12-point online clinic checklist.
Where a prescription pathway fits
Sermorelin is the most common prescription peptide men ask about because a version was once FDA-approved, which gives compounders a recognized starting point. Our sermorelin online guide covers how that pathway works. If you want a clinician to make that call, this is the telehealth service we link to:
Dosing for prescription peptides is set by the prescribing clinician. Research-use-only peptides are not sold for human use and have no approved human dose. See our medical disclaimer.
Sources
- FDA, Information for outsourcing facilities (definition, CGMP, inspection, reporting).
- FDA, Notice to compounders: changes that affect compounding on March 23, 2020.
- FDA, List of approved NDAs for biological products deemed to be BLAs on March 23, 2020.
- FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026).
Frequently Asked
A 503A pharmacy compounds for an identified patient with a prescription and is overseen mainly by its state board of pharmacy. A 503B outsourcing facility registers with FDA, can make sterile batches without patient-specific prescriptions, must follow CGMP, and is inspected by FDA on a risk-based schedule.
No. Products from both 503A pharmacies and 503B outsourcing facilities are compounded drugs, and compounded drugs are not FDA-approved. 503B adds manufacturing-quality requirements, not a review of whether the drug works.
An advisory committee vote is a non-binding recommendation. Under 503A, a bulk substance becomes eligible through FDA's bulks list, which requires FDA action after the committee meeting. Check the current status of the 503A bulks list before trusting any clinic's claim that BPC-157 is now available as a compounded prescription.
FDA's position is that biological products are not eligible for the compounding exemptions. Chorionic gonadotropin and tesamorelin are both on FDA's list of products that were deemed biologics on March 23, 2020.
FDA publishes a list of registered outsourcing facilities on its human drug compounding pages. Search the facility name your clinic gives you, and separately confirm the pharmacy is licensed in your state through your state board of pharmacy.